RHYTHM PHARMACEUTICALS, INC. (RYTM) research
RHYTHM PHARMACEUTICALS, INC.- Sector
- Biotechnology
- Last price
- $92.83
- As of
RHYTHM PHARMACEUTICALS, INC. (RYTM): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-08-04.
As of . Source: SEC EDGAR filings for RYTM. Method and limitations.
Share the RYTM intelligence card
See the full RYTM dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RYTM on one page. Preview it with sample data, then open it live with a free account.
Preview the RYTM dossierActive signals for RYTM
- highCONSENSUS_SELL
3 tracked funds reduced RYTM this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 51% of RYTM (2026Q2)
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 74% of RYTM (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 64% of RYTM (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +2480% to RYTM (2026Q2)
FREE, NO ACCOUNT
Every signal on RYTM, as it fires
You are seeing 5 of 14 signals recorded on RYTM since 2026-06-05.
The five above all landed on 2026-08-16. The other 9 were recorded on 4 other days. 7 of the 14 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in RYTM (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 76243J105 · 2026Q2 | $140.3M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP 76243J105 · 2026Q2 | $46M | 0.05% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 76243J105 · 2026Q2 | $35.2M | 0.01% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 76243J105 · 2026Q2 | $7.6M | 0.01% | , |
| D. E. Shaw & Co., Inc.CUSIP 76243J105 · 2026Q2 | $3.3M | 0.00% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 76243J105 · 2026Q2 | $511K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RYTM
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
RYTM against its peers
RYTM's operating margin of -101.2% ranks in the 32nd percentile of 13 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | RYTM | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 190M USD | 379M USD | 44 | 16 |
| Operating margin | -101.2% | -4.2% | 32 | 13 |
| Net margin | -103.6% | -5.2% | 32 | 13 |
| Return on equity | -141.3% | -22.3% | 10 | 23 |
Peers (24): ALKS, BLTE, IMVT, LGND, CNTA, GRAL, CGON, SYRE, IONS, SRRK, KOD, PRAX, MIRM, ORKA, TVTX, COGT, PTCT, CRSP, ABVX, TGTX, PCVX, APLS, DFTX, CAI. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (RYTM: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more RYTM signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to RYTMand get the insider, 13F, options, and confluence read in one view.